We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Amphion Innovations Plc | LSE:AMP | London | Ordinary Share | GB00B0DJNP99 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.15 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2020 to Jan 2025
TIDMAMP
RNS Number : 8862B
Amphion Innovations PLC
12 June 2019
AMPHION INNOVATIONS PLC
("Amphion" or "the Company")
Loan facility update
12 June 2019, London and New York - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces an update in respect of its loan facility.
The Company has been notified by the Company's debt provider (the "Lender") that, further to the terms of the loan facility which were announced on 11 March 2019 and 1 April 2019 (the "Facility"), the excess value of the collateral above the loan balance does not presently meet the terms of the Facility. As of 11 June 2019, the loan balance outstanding pursuant to the Facility is approximately US $3.2 million (including fees and accrued interest) and the number of Motif shares held was 10,900,591. The Board is working closely with the Lender regarding potential resolution in connection with the collateral requirement and further announcements will be made as appropriate.
The Company remains highly cash constrained and continues to consider both its short term and medium term funding options and work with the Company's note holders. The outstanding Facility balance plus accrued interest are currently due for repayment on 30 September 2019.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information please contact:
Amphion Innovations Tel: +1 (212) 210 6224 Charlie Morgan Panmure Gordon Limited (Nominated Adviser Tel: +44 (0)20 and Corporate Broker) 7886 2500 Emma Earl/ Freddy Crossley (Corporate Finance) Charles Leigh-Pemberton (Corporate Broking) SP Angel Corporate Finance LLP (Joint Corporate Tel: +44 (0) 20 Broker) 3470 0470 David Hignell (Corporate Finance) Vadim Alexandre (Corporate Broking) Walbrook PR Tel: +44 (0)20 7933 8780 or amphion@walbrookpr.com Anna Dunphy / Paul McManus
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.
On the web: www.amphionplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCEANKFFALNEFF
(END) Dow Jones Newswires
June 12, 2019 02:00 ET (06:00 GMT)
1 Year Amphion Innovations Chart |
1 Month Amphion Innovations Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
